FT
Therapeutic Areas
Immutep Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Eftilagimod alfa (efti) | 1st Line Non-Small Cell Lung Cancer (NSCLC) | Phase III |
| IMP761 | Autoimmune Diseases (e.g., Lupus, RA) | Preclinical |
| IMP731 | Ulcerative Colitis, Psoriasis | Phase II |
| LAG525 (ieramilimab) | Various Solid Tumors | Phase II |
| Novel Small Molecule LAG-3 Antagonist | Oncology | Research |